[go: up one dir, main page]

PL1695965T3 - Postać krystaliczna beta chlorowodorku iwabradyny, sposób jej wytwarzania i zawierające je kompozycje farmaceutyczne - Google Patents

Postać krystaliczna beta chlorowodorku iwabradyny, sposób jej wytwarzania i zawierające je kompozycje farmaceutyczne

Info

Publication number
PL1695965T3
PL1695965T3 PL06290326T PL06290326T PL1695965T3 PL 1695965 T3 PL1695965 T3 PL 1695965T3 PL 06290326 T PL06290326 T PL 06290326T PL 06290326 T PL06290326 T PL 06290326T PL 1695965 T3 PL1695965 T3 PL 1695965T3
Authority
PL
Poland
Prior art keywords
pharamcetuical
ivabradine
chlorhydrate
preparation
composition containing
Prior art date
Application number
PL06290326T
Other languages
English (en)
Inventor
Stéphane Horvath
Marie-Noëlle Auguste
Gérard DAMIEN
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1695965(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PL1695965T3 publication Critical patent/PL1695965T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • DTEXTILES; PAPER
    • D21PAPER-MAKING; PRODUCTION OF CELLULOSE
    • D21HPULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
    • D21H27/00Special paper not otherwise provided for, e.g. made by multi-step processes
    • D21H27/10Packing paper
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/18Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00Containers, packaging elements or packages, specially adapted for particular articles or materials
    • B65D85/30Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure
    • DTEXTILES; PAPER
    • D21PAPER-MAKING; PRODUCTION OF CELLULOSE
    • D21HPULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
    • D21H21/00Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties
    • D21H21/14Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties characterised by function or properties in or on the paper
    • D21H21/16Sizing or water-repelling agents
    • DTEXTILES; PAPER
    • D21PAPER-MAKING; PRODUCTION OF CELLULOSE
    • D21HPULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
    • D21H27/00Special paper not otherwise provided for, e.g. made by multi-step processes
    • D21H27/30Multi-ply
    • D21H27/40Multi-ply at least one of the sheets being non-planar, e.g. crêped

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mechanical Engineering (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
PL06290326T 2005-02-28 2006-02-28 Postać krystaliczna beta chlorowodorku iwabradyny, sposób jej wytwarzania i zawierające je kompozycje farmaceutyczne PL1695965T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501985A FR2882553B1 (fr) 2005-02-28 2005-02-28 Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
EP06290326A EP1695965B9 (fr) 2005-02-28 2006-02-28 Forme cristalline beta du chlorhydrate de l'ivabradine, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
PL1695965T3 true PL1695965T3 (pl) 2009-01-30

Family

ID=34954954

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06290326T PL1695965T3 (pl) 2005-02-28 2006-02-28 Postać krystaliczna beta chlorowodorku iwabradyny, sposób jej wytwarzania i zawierające je kompozycje farmaceutyczne

Country Status (43)

Country Link
US (3) US7361649B2 (pl)
EP (1) EP1695965B9 (pl)
JP (1) JP4625776B2 (pl)
KR (1) KR100827502B1 (pl)
CN (1) CN1827600B (pl)
AP (1) AP1907A (pl)
AR (1) AR053147A1 (pl)
AT (1) ATE407926T1 (pl)
BR (1) BRPI0600623A (pl)
CA (1) CA2537414C (pl)
CO (1) CO5770096A1 (pl)
CR (1) CR8248A (pl)
CU (1) CU23614B7 (pl)
CY (1) CY1109072T1 (pl)
DE (1) DE602006002624D1 (pl)
DK (1) DK1695965T3 (pl)
EA (1) EA008464B1 (pl)
EC (2) ECSP066373A (pl)
ES (1) ES2313581T3 (pl)
FR (1) FR2882553B1 (pl)
GE (1) GEP20084465B (pl)
GT (1) GT200600084A (pl)
HK (1) HK1096387A1 (pl)
HR (1) HRP20080520T3 (pl)
IL (1) IL173957A0 (pl)
JO (1) JO2548B1 (pl)
MA (1) MA28131A1 (pl)
ME (1) ME01408B (pl)
MY (1) MY158128A (pl)
NO (1) NO338370B1 (pl)
NZ (1) NZ545576A (pl)
PE (1) PE20061009A1 (pl)
PL (1) PL1695965T3 (pl)
PT (1) PT1695965E (pl)
RS (1) RS50661B (pl)
SA (1) SA06270038B1 (pl)
SG (1) SG125228A1 (pl)
SI (1) SI1695965T1 (pl)
TW (1) TWI314144B (pl)
UA (1) UA80904C2 (pl)
UY (1) UY29405A1 (pl)
WO (1) WO2006092493A1 (pl)
ZA (1) ZA200601762B (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
EP2460797A3 (en) 2006-11-30 2012-12-05 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
FR2911279B1 (fr) * 2007-01-11 2009-03-06 Servier Lab Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
EP2471780B1 (en) 2007-05-30 2014-11-26 Ind-Swift Laboratories Limited Crystalline Ivabradine Oxalate Salts and Polymorphs Thereof
FR2938194B1 (fr) * 2008-11-07 2012-08-31 Servier Lab Utilisation de l'ivabradine comme agent de diagnostic dans la methode d'angiographie coronaire par tomodensitometrie multicoupe
ES2402765T3 (es) 2008-12-22 2013-05-08 Krka, D.D., Novo Mesto Procedimiento de preparación de ivabradina
CN101774969B (zh) * 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
WO2011098582A2 (en) 2010-02-12 2011-08-18 Krka, D.D., Novo Mesto Novel forms of ivabradine hydrochloride
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
TWI499587B (zh) * 2010-06-03 2015-09-11 Jiangsu Hengrui Medicine Co 硫酸伊伐佈雷定及其i型結晶的製備方法
EP2579859B1 (en) 2010-06-14 2015-08-05 ratiopharm GmbH Solid ivabradine-containing composition
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
CN102304088B (zh) * 2011-07-07 2013-06-19 石药集团欧意药业有限公司 一种伊伐布雷定化合物、制备方法及其药物组合物
WO2013017582A1 (en) 2011-08-02 2013-02-07 Sandoz Ag Acetone solvate of ivabradine hydrochloride
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
EP3156399A1 (en) * 2011-11-14 2017-04-19 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
US9409913B2 (en) * 2012-11-21 2016-08-09 Enaltec Labs Private Limited Polymorphic forms of alcaftadine
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
HUE047705T2 (hu) 2013-03-19 2020-05-28 Chemo Res S L Ivabradin-hidroklorid új polimorfja és eljárás elõállítására
CZ2013767A3 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
WO2015001133A1 (en) 2013-12-12 2015-01-08 Synthon B.V. Pharmaceutical composition comprising amorphous ivabradine
EP2774606B1 (en) 2014-02-14 2019-01-30 Synthon B.V. Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV
CZ305436B6 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2016102423A1 (en) 2014-12-22 2016-06-30 Ratiopharm Gmbh Composition comprising ivabradine in a dissolved form
GR1008821B (el) 2015-06-11 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει υδροχλωρικη ιβαμπραδινη και μεθοδος παρασκευης αυτου
CN107056706B (zh) * 2015-12-21 2020-05-05 江苏恒瑞医药股份有限公司 一种用于制备盐酸伊伐布雷定α晶型的方法
US11273162B2 (en) * 2016-04-01 2022-03-15 Mississippi State University Compositions and methods targeting HCN channels for breathing therapeutics
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
US20230181472A1 (en) 2018-10-30 2023-06-15 Amgen Inc. Process of making ivabradine hydrochloride drug product
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl
CA3240614A1 (en) 2021-12-31 2023-07-06 Stuart Rich Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US4490369A (en) * 1981-05-19 1984-12-25 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Benzazepine derivatives, their pharmaceutical compositions and method of use
ES2184729T3 (es) 1990-08-29 2003-04-16 Humanetics Corp Proceso de tratamiento para promover la perdida de peso empleandio un 5-androsteno.
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2818552B1 (fr) 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
FR2834896B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'ivabradine
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
CU20060039A7 (es) 2008-06-30
UY29405A1 (es) 2006-07-31
AP2006003519A0 (en) 2006-02-28
NO20060946L (no) 2006-08-29
CO5770096A1 (es) 2007-06-29
EP1695965B1 (fr) 2008-09-10
IL173957A0 (en) 2006-07-05
TWI314144B (en) 2009-09-01
AU2006200856A1 (en) 2010-01-28
ES2313581T3 (es) 2009-03-01
GEP20084465B (en) 2008-08-25
EA008464B1 (ru) 2007-06-29
WO2006092493A1 (fr) 2006-09-08
GT200600084A (es) 2006-11-22
MA28131A1 (fr) 2006-09-01
NO338370B1 (no) 2016-08-15
CN1827600B (zh) 2010-08-11
HRP20080520T3 (en) 2009-01-31
AP1907A (en) 2008-10-23
EP1695965A1 (fr) 2006-08-30
ECSP066373A (es) 2006-10-17
JP4625776B2 (ja) 2011-02-02
ATE407926T1 (de) 2008-09-15
CY1109072T1 (el) 2014-07-02
CA2537414C (fr) 2010-02-16
PE20061009A1 (es) 2006-11-18
US20060194962A1 (en) 2006-08-31
DK1695965T3 (da) 2008-12-15
US7361649B2 (en) 2008-04-22
AR053147A1 (es) 2007-04-25
SA06270038B1 (ar) 2010-03-29
FR2882553B1 (fr) 2007-05-04
US20080161285A1 (en) 2008-07-03
US7879842B2 (en) 2011-02-01
SG125228A1 (en) 2006-09-29
CR8248A (es) 2008-10-06
KR100827502B1 (ko) 2008-05-06
DE602006002624D1 (de) 2008-10-23
CN1827600A (zh) 2006-09-06
KR20060095501A (ko) 2006-08-31
EP1695965B9 (fr) 2009-03-04
PT1695965E (pt) 2008-10-08
RS50661B (sr) 2010-06-30
MY158128A (en) 2016-08-30
UA80904C2 (en) 2007-11-12
ME01408B (me) 2010-06-30
FR2882553A1 (fr) 2006-09-01
ECSP066375A (es) 2006-11-16
EA200600322A1 (ru) 2006-08-25
CA2537414A1 (fr) 2006-08-28
NZ545576A (en) 2007-01-26
CU23614B7 (es) 2011-01-27
US20100041640A1 (en) 2010-02-18
JP2006241154A (ja) 2006-09-14
ZA200601762B (en) 2007-04-25
JO2548B1 (en) 2010-09-05
SI1695965T1 (sl) 2009-02-28
TW200640873A (en) 2006-12-01
BRPI0600623A (pt) 2006-10-24
HK1096387A1 (en) 2007-06-01

Similar Documents

Publication Publication Date Title
PL1695965T3 (pl) Postać krystaliczna beta chlorowodorku iwabradyny, sposób jej wytwarzania i zawierające je kompozycje farmaceutyczne
PL1707562T3 (pl) Forma krystaliczna gamma chlorowodorku iwabradyny, sposób jej wytwarzania oraz kompozycje farmaceutyczne, które ją zawierają
ME01394B (me) Kristalni oblik gama-d ivabradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže
SI1752443T1 (sl) Nova kristalinična oblika V agomelatina, postopek za njeno pripravo in farmacevtski sestavki, ki jo vsebujejo
RS55499B1 (sr) Novi kristalni oblik iii agomelatina, postupak njegove proizvodnje i farmaceutske kompozicije koje ga sadrže
HUS2400009I1 (hu) Glükopiranozil-helyettesített benzonitril-származékok, ilyen vegyületeket tartalmazó gyógyászati készítmények, alkalmazásuk és elõállításukra alkalmas eljárás
PL1695710T3 (pl) Postać krystaliczna beta-d chlorowodorku iwabradyny, sposób jej otrzymywania i zawierające je kompozycje farmaceutyczne
AP2185A (en) de, a process for its preparation and pharmaceuticDelta d crystalline form of ivabradine hydrochlorial compositions containing it.
IL178544A (en) Crystalline form - δ of ivabradine hydrochloride, process for preparation and pharmaceutical preparations containing it
ZA200606455B (en) Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
ZA200703277B (en) Novel pyrimidine compounds, process for their preparation and compositions containing them
IL193385A0 (en) Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
ZA200706865B (en) Miocroporous crystalline material, zeolite ITQ-33, preparation method thereof and use of same
ZA200804802B (en) Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
HK1126190A1 (en) Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them
IL203433A (en) Process for Preparing Pharmaceutical and Solid Release Controlled Compositions Containing Oxacarbazapine
IL189177A0 (en) Process for producing carcosporamide and pharmaceutical compositions containing cercosporamide
ZA200807712B (en) Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
HK1112242A1 (en) Process for the preparation of precursors of 5-alkylthioalkylamino-1- phenyl-pyrazoles 5-